Journal article
Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
Abstract
Activating mutations in Kirsten rat sarcoma viral oncogene homologue (KRAS), in particular, a point mutation leading to a glycine-to-cysteine substitution at codon 12 (G12C), are among the most frequent genomic alterations in non-small cell lung cancer (NSCLC). Several agents targeting KRAS G12C have recently entered clinical development. Sotorasib, a first-in-class specific small molecule that irreversibly inhibits KRAS G12C, has since …
Authors
Cheema PK; Banerji SO; Blais N; Chu QS-C; Juergens RA; Leighl NB; Sacher A; Sheffield BS; Snow S; Vincent M
Journal
Current Oncology, Vol. 30, No. 7, pp. 6473–6496
Publisher
MDPI
DOI
10.3390/curroncol30070476
ISSN
1198-0052